Renal transplantation, past, present and future.

Area of Science:

• Immunology
• Transplantation Medicine
• Pharmacology

Background:

• Renal transplantation success has dramatically improved over 40 years due to evolving immunosuppressive strategies.
• Early immunosuppression with glucocorticoids and azathioprine led to high rejection and infection rates.
• Advances in molecular immunology have driven the discovery of more specific immunosuppressive agents.

Purpose of the Study:

• To review the evolution of immunosuppressive drug regimens in renal transplantation.
• To highlight the impact of new immunosuppressive agents on graft survival and rejection rates.
• To discuss current challenges and future directions in immunosuppression, including the pursuit of immunological tolerance.

Main Methods:

• Historical review of immunosuppressive drug development in transplantation.
• Analysis of clinical trial outcomes for various immunosuppressive regimens.
• Discussion of emerging immunosuppressive agents and tolerance-inducing strategies.

Main Results:

• Modern immunosuppression achieves 1-year graft survival of 80-90%, a significant improvement over historical methods.
• Introduction of agents like cyclosporine and monoclonal antibodies improved rejection control.
• Newer drugs (tacrolimus, rapamycin, mycophenolate mofetil) offer more selective T- and B-cell targeting.
• Combination therapies and steroid-sparing protocols reduced acute rejection to <10%.

Conclusions:

• Current immunosuppression has transformed kidney transplantation into a routine procedure.
• The primary challenge is managing long-term side effects of prolonged immunosuppression, such as infections and malignancies.
• Future research focuses on achieving immunological tolerance to minimize immunosuppressive therapy and its associated risks.